Amedeo Smart

Free Medical Literature Service


 

Amedeo

Bladder Cancer

  Free Subscription

Articles published in
Cancer
    July 2021
  1. LAWLER C, Gu L, Howard LE, Branche B, et al
    The impact of the social construct of race on outcomes among bacille Calmette-Guerin-treated patients with high-risk non-muscle-invasive bladder cancer in an equal-access setting.
    Cancer. 2021 Jul 8. doi: 10.1002/cncr.33792.
    >> Share

    March 2021
  2. PRINTZ C
    Liquid biopsy test appears better at detecting bladder cancer than urine cytology.
    Cancer. 2021;127:663.
    >> Share

    November 2020
  3. GARG T, McMullen CK, Leo MC, O'Keeffe-Rosetti MC, et al
    Predicting risk of multiple levels of recurrence and progression after initial diagnosis of nonmuscle-invasive bladder cancer in a multisite, community-based cohort.
    Cancer. 2020 Nov 4. doi: 10.1002/cncr.33300.
    >> Share

    June 2020
  4. PAL SK, Bajorin D, Dizman N, Hoffman-Censits J, et al
    Infigratinib in upper tract urothelial carcinoma versus urothelial carcinoma of the bladder and its association with comprehensive genomic profiling and/or cell-free DNA results.
    Cancer. 2020;126:2597-2606.
    >> Share

    January 2020
  5. O'DONNELL PH, Arkenau HT, Sridhar SS, Ong M, et al
    Patient-reported outcomes and inflammatory biomarkers in patients with locally advanced/metastatic urothelial carcinoma treated with durvalumab in phase 1/2 dose-escalation study 1108.
    Cancer. 2020;126:432-443.
    >> Share

    October 2019
  6. FLETCHER SA, Cole AP, Lu C, Marchese M, et al
    The impact of underinsurance on bladder cancer diagnosis, survival, and care delivery for individuals under the age of 65 years.
    Cancer. 2019 Oct 18. doi: 10.1002/cncr.32562.
    >> Share

    August 2019
  7. ZHENG J, Kong J, Wu S, Li Y, et al
    Development of a noninvasive tool to preoperatively evaluate the muscular invasiveness of bladder cancer using a radiomics approach.
    Cancer. 2019 Aug 30. doi: 10.1002/cncr.32490.
    >> Share

    July 2019
  8. TAKAHASHI T
    Overall survival is the primary endpoint in a trial of neoadjuvant chemotherapy for bladder cancer?
    Cancer. 2019 Jul 29. doi: 10.1002/cncr.32415.
    >> Share

    May 2019
  9. MARTINI A, Jia R, Ferket BS, Waingankar N, et al
    Tumor downstaging as an intermediate endpoint to assess the activity of neoadjuvant systemic therapy in patients with muscle-invasive bladder cancer.
    Cancer. 2019 May 31. doi: 10.1002/cncr.32169.
    >> Share

  10. SCHROECK FR, Lynch KE, Li Z, MacKenzie TA, et al
    The impact of frequent cystoscopy on surgical care and cancer outcomes among patients with low-risk, non-muscle-invasive bladder cancer.
    Cancer. 2019 May 23. doi: 10.1002/cncr.32185.
    >> Share

  11. BERG S, D'Andrea D, Vetterlein MW, Cole AP, et al
    Impact of adjuvant chemotherapy in patients with adverse features and variant histology at radical cystectomy for muscle-invasive carcinoma of the bladder: Does histologic subtype matter?
    Cancer. 2019;125:1449-1458.
    >> Share

    March 2019
  12. CHU AT, Holt SK, Wright JL, Ramos JD, et al
    Delays in radical cystectomy for muscle-invasive bladder cancer.
    Cancer. 2019 Mar 6. doi: 10.1002/cncr.32048.
    >> Share

  13. MASIC S, Smaldone MC
    Treatment delays for muscle-invasive bladder cancer.
    Cancer. 2019 Mar 6. doi: 10.1002/cncr.32047.
    >> Share

    January 2019
  14. COLE AP, Fletcher SA, Berg S, Nabi J, et al
    Impact of tumor, treatment, and access on outcomes in bladder cancer: Can equal access overcome race-based differences in survival?
    Cancer. 2019 Jan 11. doi: 10.1002/cncr.31926.
    >> Share

  15. VANTAKU V, Donepudi SR, Piyarathna DWB, Sekhar Amara C, et al
    Large-scale profiling of serum metabolites in African American and European American patients with bladder cancer reveals metabolic pathways associated with patient survival.
    Cancer. 2019 Jan 2. doi: 10.1002/cncr.31890.
    >> Share

    December 2018
  16. GARG T, Young AJ, O'Keeffe-Rosetti M, McMullen CK, et al
    Reply to Association between treatment of superficial bladder cancer and 10-year mortality in older adults with multiple chronic conditions.
    Cancer. 2018 Dec 5. doi: 10.1002/cncr.31894.
    >> Share

  17. BRYAN RT
    Association between treatment of superficial bladder cancer and 10-year mortality in older adults with multiple chronic conditions.
    Cancer. 2018 Dec 5. doi: 10.1002/cncr.31888.
    >> Share

    October 2018
  18. WOLDU SL, Sanli O, Clinton TN, Lotan Y, et al
    Validating the predictors of outcomes after radical cystectomy for bladder cancer.
    Cancer. 2018 Oct 6. doi: 10.1002/cncr.31799.
    >> Share

  19. GARG T, Young AJ, O'Keeffe-Rosetti M, McMullen CK, et al
    Association between treatment of superficial bladder cancer and 10-year mortality in older adults with multiple chronic conditions.
    Cancer. 2018 Oct 5. doi: 10.1002/cncr.31705.
    >> Share

    May 2018
  20. SMITH AB, Chisolm S, Deal A, Spangler A, et al
    Patient-centered prioritization of bladder cancer research.
    Cancer. 2018 May 4. doi: 10.1002/cncr.31530.
    >> Share

    April 2018
  21. JAZZAR U, Yong S, Klaassen Z, Huo J, et al
    Impact of psychiatric illness on decreased survival in elderly patients with bladder cancer in the United States.
    Cancer. 2018 Apr 16. doi: 10.1002/cncr.31404.
    >> Share

  22. CORREA AF, Smaldone MC
    Melancholia and cancer: The bladder cancer narrative.
    Cancer. 2018 Apr 16. doi: 10.1002/cncr.31402.
    >> Share

    January 2018
  23. CHOUDHURY A, Hoskin PJ
    Bladder cancer and the National Cancer Data Base: New insight or misinformation?
    Cancer. 2018 Jan 16. doi: 10.1002/cncr.31210.
    >> Share

    December 2017
  24. WELTY CJ, Sanford TH, Wright JL, Carroll PR, et al
    The Cancer of the Bladder Risk Assessment (COBRA) score: Estimating mortality after radical cystectomy.
    Cancer. 2017;123:4574-4582.
    >> Share

    July 2017
  25. CAHN DB, Handorf EA, Ghiraldi EM, Ristau BT, et al
    Contemporary use trends and survival outcomes in patients undergoing radical cystectomy or bladder-preservation therapy for muscle-invasive bladder cancer.
    Cancer. 2017 Jul 25. doi: 10.1002/cncr.30900.
    >> Share

  26. VETTERLEIN MW, Wankowicz SAM, Seisen T, Lander R, et al
    Neoadjuvant chemotherapy prior to radical cystectomy for muscle-invasive bladder cancer with variant histology.
    Cancer. 2017 Jul 25. doi: 10.1002/cncr.30907.
    >> Share

  27. KOPP RP, Stratton KL, Glogowski E, Schrader KA, et al
    Utility of prospective pathologic evaluation to inform clinical genetic testing for hereditary leiomyomatosis and renal cell carcinoma.
    Cancer. 2017;123:2452-2458.
    >> Share

  28. PIATON E, Advenier AS, Carre C, Decaussin-Petrucci M, et al
    p16/Ki-67 dual labeling and urinary cytology results according to the New Paris System for Reporting Urinary Cytology: Impact of extended follow-up.
    Cancer. 2017;125:552-562.
    >> Share

    June 2017
  29. OJERHOLM E, Smith A, Hwang WT, Christodouleas JP, et al
    Reply to Neutrophil-to-lymphocyte ratio as a bladder cancer biomarker: Assessing prognostic and predictive value in SWOG 8710.
    Cancer. 2017 Jun 30. doi: 10.1002/cncr.30871.
    >> Share

  30. DOLAN RD, McMillan DC
    Neutrophil-to-lymphocyte ratio as a bladder cancer biomarker: Assessing prognostic and predictive value in SWOG 8710.
    Cancer. 2017 Jun 30. doi: 10.1002/cncr.30872.
    >> Share

  31. KORPICS MC, Block AM, Martin B, Hentz C, et al
    Concurrent chemotherapy is associated with improved survival in elderly patients with bladder cancer undergoing radiotherapy.
    Cancer. 2017 Jun 5. doi: 10.1002/cncr.30719.
    >> Share

  32. RIMAR KJ, Tran PT, Matulewicz RS, Hussain M, et al
    The emerging role of homologous recombination repair and PARP inhibitors in genitourinary malignancies.
    Cancer. 2017;123:1912-1924.
    >> Share

  33. SCOTT SN, Ostrovnaya I, Lin CM, Bouvier N, et al
    Next-generation sequencing of urine specimens: A novel platform for genomic analysis in patients with non-muscle-invasive urothelial carcinoma treated with bacille Calmette-Guerin.
    Cancer. 2017;125:416-426.
    >> Share

    February 2017
  34. PACKIAM VT, Johnson SC, Steinberg GD
    Non-muscle-invasive bladder cancer: Intravesical treatments beyond Bacille Calmette-Guerin.
    Cancer. 2017;123:390-400.
    >> Share

  35. WANG H, Hoda RS, Faquin W, Rossi ED, et al
    FNA biopsy of secondary nonlymphomatous malignancies in salivary glands: A multi-institutional study of 184 cases.
    Cancer. 2017;125:91-103.
    >> Share

  36. MACLEOD LC, Pham KN, Agoff SN, Dahl KL, et al
    Cytologic persistence of malignant cells after transurethral resection of bladder tumors: Implications for concomitant manipulation of the urinary tract at the time of endoscopic resection.
    Cancer. 2017;125:114-119.
    >> Share

    October 2016
  37. OJERHOLM E, Smith A, Hwang WT, Baumann BC, et al
    Neutrophil-to-lymphocyte ratio as a bladder cancer biomarker: Assessing prognostic and predictive value in SWOG 8710.
    Cancer. 2016 Oct 27. doi: 10.1002/cncr.30422.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016